H. Lundbeck A/S

Copenhagen Stock Exchange:HLUN-B.CO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Denmark

Market Cap

USD 5.35 B

Share Price

USD 5.60

Avg Daily Volume

582,647

Change (1 day)

0.14%

Change (1 year)

2.60%

Change (YTD)

-2.56%

H. Lundbeck A/S Depreciation And Amortization for the year ending December 31, 2024: USD 259.64 M

H. Lundbeck A/S Depreciation And Amortization is USD 259.64 M for the year ending December 31, 2024, a -12.82% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.

H. Lundbeck A/S Depreciation And Amortization for the year ending December 31, 2023 was USD 297.82 M, a 14.60% change year over year.
H. Lundbeck A/S Depreciation And Amortization for the year ending December 31, 2022 was USD 259.88 M, a -0.57% change year over year.
H. Lundbeck A/S Depreciation And Amortization for the year ending December 31, 2021 was USD 261.36 M, a -42.87% change year over year.
H. Lundbeck A/S Depreciation And Amortization for the year ending December 31, 2020 was USD 457.49 M, a 83.00% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Depreciation And Amortization	Dividends Paid	Common Stock Issued	Common Stock Repurchased

Copenhagen Stock Exchange: HLUN-B.CO

H. Lundbeck A/S

CEO	Mr. Charl van Zyl
IPO Date	June 10, 2022
Location	Denmark
Headquarters	Ottiliavej 9
Employees	5,707
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.